RESUMEN
PURPOSE: Carcinoid heart disease (CHD) is a life-threatening complication of carcinoid syndrome (CS) characterised by tricuspid regurgitation (TR). However, there is an unmet need for earlier diagnosis of CHD. We cross-sectionally assessed the prevalence and potential predictive or diagnostic markers for CS and CHD in a contemporary cohort of patients with small intestinal neuroendocrine tumours (SI-NETs). METHODS: Biochemical characteristics, hepatic tumour load, measures of arterial and endothelial function, atherosclerosis, and transthoracic echocardiography were analysed in a prospective cross-sectional setting. RESULTS: Among the 65 patients studied, 29 (45%) had CS (CS+ ), and 3 (5%) CHD. CS+ was characterised by significantly higher hepatic tumour load, S-5-HIAA and fP-CgA, higher frequency of diarrhoea and flushing, and more frequent PRRT compared to CS- (for all, P < 0.05). Central systolic, central mean, and central end-systolic blood pressures were significantly higher in CS+ than in CS- (for all, P < 0.05). Subjects with grades 2-4 TR had higher hepatic tumour burden, fP-CgA, and S-5-HIAA compared to those with grades 0-1 TR, but measures of vascular function did not differ. fP-CgA (P = 0.017) and S-5-HIAA (P = 0.019) but not proBNP increased significantly according to the severity of TR. CONCLUSION: Although CS is common, the prevalence of CHD was found to be lower in a contemporary cohort of SI-NET patients than previously anticipated. Measures of arterial or endothelial function or carotid atherosclerosis do not identify subjects with mild TR. Echocardiography remains the most sensitive means to diagnose CHD in CS patients with high tumour burden and elevated CgA and 5-HIAA.
Asunto(s)
Cardiopatía Carcinoide , Tumor Carcinoide , Neoplasias Intestinales , Neoplasias Hepáticas , Síndrome Carcinoide Maligno , Tumores Neuroendocrinos , Biomarcadores , Cardiopatía Carcinoide/diagnóstico , Cardiopatía Carcinoide/diagnóstico por imagen , Estudios Transversales , Humanos , Ácido Hidroxiindolacético , Neoplasias Intestinales/complicaciones , Neoplasias Intestinales/diagnóstico , Síndrome Carcinoide Maligno/complicaciones , Síndrome Carcinoide Maligno/diagnóstico , Síndrome Carcinoide Maligno/epidemiología , Tumores Neuroendocrinos/complicaciones , Tumores Neuroendocrinos/diagnóstico , Tumores Neuroendocrinos/patología , Estudios ProspectivosRESUMEN
BACKGROUND: Radiation-associated angiosarcoma of the breast (RAASB) is a serious late consequence caused by breast cancer treatment. Initial symptoms are often inconspicuous, thus contributing to diagnostic delay. Most previous studies of the diagnostic aspects of RAASB are case reports. PURPOSE: To perform a complete review of the imaging findings and biopsy methods in a nationwide RAASB cohort. MATERIAL AND METHODS: RAASB patients were identified from a national cancer registry and additional patients were included from our hospital. All available information from imaging (mammogram [MGR], ultrasound [US], magnetic resonance imaging [MRI], and computed tomography [CT]) and biopsies was reviewed. The sensitivity of imaging and biopsy methods for detection of RAASB was calculated. RESULTS: Fifty-eight patients with RAASB were found. Fourteen MGR, 30 US, 24 MRI, and 25 CT studies were available for evaluation. The sensitivity of MGR, US, MRI, and CT for detection of RAASB was 43%, 50%, 92%, and 84%, respectively. Superior sensitivity was demonstrated for punch biopsy (84%) and incisional biopsy (93%) compared to fine-needle aspiration cytology (0%) and core needle biopsy (18%). CONCLUSION: MRI and CT have comparable sensitivity for detection of RAASB, while MGR and US are unreliable. However, negative findings in MRI or CT must be interpreted with caution. Punch biopsy and incisional biopsy are the preferred biopsy methods.
Asunto(s)
Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/etiología , Hemangiosarcoma/diagnóstico por imagen , Hemangiosarcoma/etiología , Neoplasias Inducidas por Radiación/diagnóstico por imagen , Anciano , Biopsia , Medios de Contraste , Femenino , Finlandia , Humanos , Interpretación de Imagen Asistida por Computador , Imagen por Resonancia Magnética , Sistema de Registros , Estudios Retrospectivos , Sensibilidad y Especificidad , Tomografía Computarizada por Rayos XRESUMEN
BACKGROUND: Radiation-associated angiosarcoma of the breast (RAASB) is an aggressive malignancy that is increasing in incidence. Only a few previous population-based studies have reported the results of RAASB treatment. METHODS: A search for RAASB patients was carried out in the Finnish Cancer Registry, and treatment data were collected to identify prognostic factors for survival. RESULTS: Overall, 50 RAASB patients were identified. The median follow-up time was 5.4 years (range 0.4-15.6), and the 5-year overall survival rate was 69%. Forty-seven (94%) patients were operated on with curative intent. Among these patients, the 5-year local recurrence-free survival, distant recurrence-free survival, and overall survival rates were 62%, 75%, and 74%, respectively. A larger planned surgical margin was associated with improved survival. CONCLUSIONS: We found that the majority of RAASB patients were eligible for radical surgical management in this population-based analysis. With radical surgery, the prognosis is relatively good.
Asunto(s)
Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/cirugía , Hemangiosarcoma/mortalidad , Hemangiosarcoma/cirugía , Neoplasias Inducidas por Radiación/mortalidad , Neoplasias Inducidas por Radiación/cirugía , Radioterapia/efectos adversos , Anciano , Terapia Combinada , Supervivencia sin Enfermedad , Femenino , Finlandia/epidemiología , Humanos , Mastectomía , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Sistema de Registros , Tasa de SupervivenciaAsunto(s)
Atención Ambulatoria/psicología , Hematología/estadística & datos numéricos , Enfermería Oncológica/estadística & datos numéricos , Pacientes Ambulatorios/psicología , Prioridad del Paciente/psicología , Prioridad del Paciente/estadística & datos numéricos , Adulto , Anciano , Anciano de 80 o más Años , Atención Ambulatoria/estadística & datos numéricos , Femenino , Finlandia , Humanos , Masculino , Persona de Mediana Edad , Pacientes Ambulatorios/estadística & datos numéricosRESUMEN
A single-institution series using a (neo)adjuvant chemotherapy and interdigitated hyperfractionated split-course radiation therapy (CRT) treatment protocol for soft tissue sarcoma was reviewed. Our specific aims were to study recurrence rates and long-term toxicity. Between 1998 and 2016, 89 patients with non-metastatic soft tissue sarcoma were treated with surgery combined with six courses of doxorubicin and ifosfamide and hyperfractionated radiation therapy (42-60 Gy/1.5 Gy twice daily). Patients were considered being at high risk if tumour malignancy grade was high and the tumour fulfilled at least two of the following criteria: size >8 cm, presence of necrosis or vascular invasion. The mean age of the patients was 50.7 years. With a median follow-up of 5.4 years for survivors, the local control rate was 81.4%. Six (7%) patients progressed during neoadjuvant CRT. Seven (8%) patients discontinued the treatment due to toxicity. Eighty-six patients were operated and three (3%) of these developed a long-term complication. The estimated metastasis-free survival was 47.6% and overall survival 53.0% at five years. The limb-salvage rate was 93%. The limb-salvage rate, local control and complication rates were good in these patients with high risk soft tissue sarcoma. Metastases-free survival and overall survival rates were less satisfactory, reflecting the aggressive nature of these tumours.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Quimioradioterapia Adyuvante/métodos , Terapia Neoadyuvante/métodos , Sarcoma/terapia , Adulto , Anciano , Amputación Quirúrgica/estadística & datos numéricos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Quimioradioterapia Adyuvante/efectos adversos , Supervivencia sin Enfermedad , Fraccionamiento de la Dosis de Radiación , Doxorrubicina/administración & dosificación , Esquema de Medicación , Femenino , Finlandia/epidemiología , Estudios de Seguimiento , Humanos , Ifosfamida/administración & dosificación , Recuperación del Miembro/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Terapia Neoadyuvante/efectos adversos , Estudios Retrospectivos , Sarcoma/mortalidad , Tasa de Supervivencia , Adulto JovenRESUMEN
BACKGROUND: A single-institution experience of pulmonary metastasectomy in soft tissue sarcoma (STS) was retrospectively reviewed. Our specific aim was to examine, whether the resection of pulmonary metastases could be curative. We also compared overall survival (OS) of patients after complete or incomplete pulmonary resection and nonsurgical treatment. METHODS: Between 1987 and 2016, 1580 patients were treated for STS with curative intent by Soft Tissue Sarcoma Group at Helsinki University Hospital, Finland. Three hundred forty-seven patients (22%) developed advanced disease and 130 STS patients (9%) developed pulmonary metastases as first systemic relapse. Seventy four patients (5%) were operated for lung metastases. RESULTS: Fifty-five patients (42%) had a complete and 19 (15%) incomplete resection. Fifty-six (43%) were unoperated. Median OS after complete or incomplete metastasectomy, chemotherapy, or best supportive care was 22, 18, 8, and 5 months, respectively. Twelve patients (9%) developed no further metastases and are alive with no evidence of disease. Disease-free survival (DFS) for completely resected patients was 17% at 5 years. All long-term survivors had oligometastatic disease and they underwent one to three complete metastasectomies. CONCLUSIONS: Complete pulmonary metastasectomy in STS results in 5 years DFS in nearly one-fifth of patients. Most of these patients are probably cured.
Asunto(s)
Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/cirugía , Metastasectomía , Neumonectomía , Sarcoma/secundario , Sarcoma/cirugía , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Neoplasias Pulmonares/mortalidad , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Sarcoma/mortalidad , Tasa de Supervivencia , Resultado del Tratamiento , Adulto JovenAsunto(s)
Neoplasias Abdominales/tratamiento farmacológico , Poliposis Adenomatosa del Colon/tratamiento farmacológico , Aminopiridinas/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Quinasa 4 Dependiente de la Ciclina/antagonistas & inhibidores , Quinasa 6 Dependiente de la Ciclina/antagonistas & inhibidores , Fibromatosis Agresiva/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/uso terapéutico , Purinas/uso terapéutico , Adulto , Femenino , Goserelina/uso terapéutico , Humanos , Letrozol/uso terapéutico , Adulto JovenRESUMEN
BACKGROUND AND OBJECTIVES: Estrogen receptor signaling and cyclin D1 have a major role in tumor cell proliferation in breast cancer. Desmoid tumors are rare neoplasms that may respond to endocrine treatment. The present study aimed to investigate the expression levels and the clinical relevance of estrogen receptor beta (ERß) and cyclin D1 in desmoid tumors. METHODS: This study consists of 83 patients with a surgically treated desmoid tumor. ERß and cyclin D1 expression was examined by immunohistochemistry in tissue microarrays. Cyclin A and Ki67 were studied in our previous work. RESULTS: Median ERß expression was 10.8%. ERß expression correlated with expression of the proliferation antigens Ki67 (rp = 0.35, P = 0.003), cyclin D1 (rp = 0.34, P = 0.004), and cyclin A (rp = 0.34, P = 0.004). ERß immunoexpression showed a trend towards predictive impact for recurrence as a continuous variable. Further explorative analysis indicated that very high ERß expression was related to high risk of relapse (hazard ratio [HR] 2.6; P = 0.02). Median cyclin D1 expression was 15.6%. High cyclin D1 expression was associated with high Ki67 and cyclin A expression. Cyclin D1 was not associated with time to recurrence. CONCLUSIONS: ERß and cyclin D1 immunopositivity correlated with high proliferation in desmoid tumors. High ERß expression might be predictive for postoperative recurrence.
Asunto(s)
Receptor beta de Estrógeno/biosíntesis , Fibromatosis Agresiva/metabolismo , Fibromatosis Agresiva/patología , Adulto , Biomarcadores de Tumor/biosíntesis , Procesos de Crecimiento Celular/fisiología , Ciclina D1/biosíntesis , Femenino , Humanos , Inmunohistoquímica , Masculino , Recurrencia Local de Neoplasia/metabolismo , Recurrencia Local de Neoplasia/patología , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Análisis de Matrices TisularesRESUMEN
BACKGROUND: The prevalence of small intestine neuroendocrine tumors (SI-NETs) is increasing. Disease progression is often slow and treatment options and long-term survival rates have improved, but little is known about health-related quality of life (HRQoL) in these patients. OBJECTIVE: To assess HRQoL and its predictors in SI-NET patients receiving contemporary treatments. METHODS: We measured HRQoL with 15D and SF-36 questionnaires in 134 SI-NET patients and compared the 15D results to those of an age- and gender-standardized sample of the general population (n = 1,153). In the patients, we studied the impact of treatments, Ki-67, liver metastases, circulating tumor markers, comorbidities, and/or socioeconomic factors on HRQoL with linear regression analysis. RESULTS: The mean disease duration of the patients was 81 (4-468) months, 91% had metastatic disease, and 79% received somatostatin analog treatment. Hepatic tumor load was 0% in 44.8%, < 10-25% in 44.0%, and > 25% in 11.2%, respectively. Mean fP-CgA and S-5HIAA concentrations were 15 (1.3-250) and 344 (24-7,470) nmol/L, respectively. Overall, HRQoL was significantly impaired in patients compared to controls (15D score 0.864 ± 0.105 vs. 0.905 ± 0.028, p < 0.001). SI-NET patients scored worse on 9 of 15 dimensions: sleep, excretion (i.e., bladder and bowel function), depression, distress, vitality, sexual activity (p < 0.001), breathing, usual activities, and discomfort and symptoms (p < 0.01-0.05). SF-36 scores were impaired and highly correlated with 15D scores (p < 0.001). HRQoL was impaired in patients with (n = 85) compared to patients without (n = 49) impaired excretion (0.828 vs. 0.933, p < 0.001). In the patient group, number of medications predicted impaired HRQoL. CONCLUSIONS: Despite contemporary treatments, SI-NET patients have severely impaired HRQoL, including diarrhea, sleep, depression, vitality, and sexual activity.
Asunto(s)
Neoplasias Intestinales/epidemiología , Intestino Delgado/patología , Tumores Neuroendocrinos/epidemiología , Calidad de Vida , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Finlandia/epidemiología , Estado de Salud , Humanos , Neoplasias Intestinales/patología , Neoplasias Intestinales/terapia , Masculino , Persona de Mediana Edad , Tumores Neuroendocrinos/patología , Tumores Neuroendocrinos/terapia , Encuestas y CuestionariosRESUMEN
Radiation-associated sarcoma (RAS) is a rare complication of radiation therapy (RT) to breast cancer (BC). This study explored RAS after RT to BC in a nationwide population-based material. The Finnish Cancer Registry was queried for patients with BC treated during 1953-2014 who were later diagnosed with a secondary sarcoma in 1953-2014. Registry data, patient files, and sarcoma specimens were analyzed to confirm diagnosis and location of RAS at or close to the RT target volume. A total of 132 512 patients were diagnosed with invasive BC during the study period. A subsequent sarcoma was diagnosed in 355 patients. After exclusion, 96 RAS were identified. Angiosarcoma (AS) was the most prevalent histology in 50 (52%) of 96 patients. However, the first radiation-associated AS was diagnosed in a patient treated for BC with breast-conserving surgery in 1984, and thereafter, the proportion of AS continuously increased. The 5-year sarcoma-specific survival was 75.1% for RAS treated with a curative intent. The distribution of histologic subtypes of RAS has changed during the 60 years of this registry study. The first radiation-associated AS was diagnosed in 1989, and presently, AS is the most common histologic subtype of RAS. It is possible that changes in BC treatment strategies are influencing the characteristics of RAS.
Asunto(s)
Neoplasias de la Mama/epidemiología , Neoplasias Inducidas por Radiación/epidemiología , Neoplasias Primarias Secundarias/epidemiología , Neoplasias Primarias Secundarias/etiología , Sarcoma/epidemiología , Sarcoma/etiología , Neoplasias de la Mama/radioterapia , Terapia Combinada , Femenino , Finlandia/epidemiología , Hemangiosarcoma/diagnóstico , Hemangiosarcoma/epidemiología , Hemangiosarcoma/etiología , Hemangiosarcoma/terapia , Humanos , Mastectomía , Neoplasias Inducidas por Radiación/terapia , Neoplasias Primarias Secundarias/terapia , Vigilancia en Salud Pública , Radioterapia/efectos adversos , Radioterapia/métodos , Sistema de Registros , Medición de Riesgo , Factores de Riesgo , Sarcoma/diagnóstico , Sarcoma/terapia , Resultado del TratamientoRESUMEN
BACKGROUND AND OBJECTIVES: Desmoid tumors are soft-tissue tumors originating from myofibroblasts with a tendency to recur after surgery. High expression of proliferation markers is associated with shortened progression-free and/or overall survival in many neoplasms, including soft-tissue sarcomas. We investigated the prognostic role of cyclin A and Ki67 in desmoid tumors by immunohistochemistry. METHODS: The study included 76 patients with desmoid tumor operated at Helsinki University Hospital between 1987 and 2011. A tissue micro array (TMA) was constructed and the TMA sections were immunostained with cyclin A and Ki67 antibodies. A computer-assisted image analysis was performed. RESULTS: Cyclin A expression was evaluable in 74 and Ki67 in 70 patients. Cyclin A immunopositivity varied from 0% to 9.9%, with a mean of 1.9%. Cyclin A expression correlated significantly with Ki67. Cyclin A expression was associated with recurrence-free survival (HR 1.9, 95% CI = 1.1-3.2, P = .02), as were positive margin (HR 6.0, 95% CI = 1.6-22.5, P = .008) and extremity location (HR 5.3, 95% CI = 1.7-16.8, P = 0.005). Ki67 immunopositivity varied from 0.33% to 13.8%, with a mean of 4.6%, but had no significant prognostic impact (HR 1.1, P = .2). CONCLUSIONS: Our study indicates that cyclin A may be a new prognostic biomarker in surgically treated desmoid tumors.
Asunto(s)
Ciclina A/biosíntesis , Fibromatosis Agresiva/metabolismo , Fibromatosis Agresiva/cirugía , Antígeno Ki-67/biosíntesis , Recurrencia Local de Neoplasia/metabolismo , Adulto , Biomarcadores de Tumor/biosíntesis , Femenino , Fibromatosis Agresiva/patología , Humanos , Inmunohistoquímica , Masculino , Recurrencia Local de Neoplasia/patología , Pronóstico , Modelos de Riesgos Proporcionales , Análisis de Matrices TisularesRESUMEN
BACKGROUND: Modularisation is a potential means to develop health care delivery by combining standardisation and customisation. However, little is known about the effects of modularisation on hospital care. The objective was to analyse how modularisation may change and support health care delivery in specialised hospital care. METHODS: A mixed methods case study methodology was applied using both qualitative and quantitative data, including interviews, field notes, documents, service usage data, bed count and personnel resource data. Data from a reference hospital's unit were used to understand the context and development of care delivery in general. RESULTS: The following outcome themes were identified from the interviews: balance between demand and supply; support in shift from inpatient to outpatient care; shorter treatment times and improved management of service production. Modularisation supported the shift from inpatient towards outpatient care. Changes in resource efficiency measures were both positive and negative; the number of patients per personnel decreased, while the number of visits per personnel and the bed utilisation rate increased. CONCLUSIONS: Modularisation may support health care providers in classifying patients and delivering services according to patients' needs. However, as the findings are based on a single university hospital case study, more research is needed.
Asunto(s)
Atención Ambulatoria , Atención a la Salud/normas , Personal de Salud , Adulto , Femenino , Finlandia , Hospitales Universitarios , Humanos , Masculino , EmbarazoRESUMEN
BACKGROUND: Desmoid tumors (aggressive fibromatosis) are rare soft tissue tumors which frequently recur after surgery. Desmoid tumors arise from musculoaponeurotic tissue in the extremities, head and neck, abdominal wall, or intra-abdominally. Our aim was to examine the outcome of radiotherapy of desmoid tumors in a single institution series. PATIENTS AND METHODS: We evaluated 41 patients with desmoid tumors treated with 49 radiotherapies between 1987 and 2012. Radiologic images for response evaluation were reassessed and responses to treatment registered according to RECIST criteria 1.1. For patients with local failures radiation dose distribution was determined in each local failure volume using image co-registration. Recurrences were classified as in-target, marginal, or out-of-target. Prognostic factors for radiotherapy treatment failure were evaluated. RESULTS: Radiotherapy doses varied from 20-63 Gy (median 50 Gy) with a median fraction size of 2 Gy. The objective response rate to definitive radiotherapy was 55% (12/22 patients). Median time to response was 14 months. A statistically significant dose-response relation for definitive and postoperative radiotherapy was observed both in univariate (p-value 0.002) and in multivariate analysis (p-value 0.02) adjusted for potential confounding factors. Surgery before radiotherapy or surgical margin had no significant effect on time to progression. Nine of 11 (82%) local failures were classified as marginal and two of 11 (18%) in-target. None of the recurrences occurred totally out-of-target. CONCLUSIONS: Radiotherapy is a valuable option for treating desmoid tumors. Radiotherapy dose appears to be significantly associated to local control.
Asunto(s)
Fibromatosis Agresiva/diagnóstico , Fibromatosis Agresiva/radioterapia , Recurrencia Local de Neoplasia/diagnóstico , Recurrencia Local de Neoplasia/prevención & control , Radioterapia Conformacional/métodos , Adolescente , Anciano , Niño , Preescolar , Supervivencia sin Enfermedad , Femenino , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Dosificación Radioterapéutica , Insuficiencia del Tratamiento , Resultado del Tratamiento , Adulto JovenRESUMEN
Although several options of drug therapy exist for advanced neuroendocrine cancer of pancreatic origin, few data based on randomized studies are available. The results of the most recent randomized placebo-controlled studies are obscured by the assignment of patients from the placebo branch to the treatment branch. Application of the study results is further hampered by small patient groups, heterogeneity and retrospective set-up of study materials and, in older studies, inaccurate response assessment. We describe drug therapies that can be utilized to affect the clinical course of locally advanced or metastatic neuroendocrine cancer of pancreatic origin. Supportive therapy of hormonally active tumors has been restricted to somatostatin analogue treatment.
Asunto(s)
Antineoplásicos/uso terapéutico , Tumores Neuroendocrinos/tratamiento farmacológico , Neoplasias Pancreáticas/tratamiento farmacológico , Somatostatina/análogos & derivados , Humanos , Tumores Neuroendocrinos/patología , Neoplasias Pancreáticas/patologíaRESUMEN
Background Giant cell tumors (GCTs) are rare osseous tumors that rarely appear in the skull. Methods We review the clinical course of a 28-year-old previously healthy woman with a complicated GCT. Results The reviewed patient presented with a middle cranial fossa tumor acutely complicated by reactive mastoiditis. Left tympanomastoidectomy was performed for drainage of the mastoiditis and for biopsies of the tumor. Due to the challenging tumor location, the patient was treated with denosumab, a fully humanized monoclonal antibody against receptor activator of nuclear factor kappa-B ligand, for 7 months, which resulted in significant preoperative tumor shrinkage. Extensive temporal craniotomy and resection of the tumor followed utilizing a temporomandibular joint total endoprosthesis for reconstruction. A recurrence of the tumor was detected on computed tomography at 19 months after surgery and treated with transtemporal tumor resection, parotidectomy, and mandible re-reconstruction. Conclusion A multidisciplinary approach resulted in a good functional result and, finally, an eradication of the challengingly located middle cranial fossa tumor.
RESUMEN
Cancers in HIV-infected patients are divided into the AIDS-defining and non-AIDS defining cancers. In the era of effective antiretroviral therapy there has been a significant decrease in the incidence of AIDS-defining cancers, whereas the number of non-AIDS defining cancers is on the rise. This is partly explained by the frequent occurrence of conventional risk factors for cancers, but also HIV infection itself seems to further increase the risk. If an HIV-infected person is diagnosed early enough, his/her life expectancy corresponds to that of the general population. Therefore the treatment goal of cancers in HIV-infected patients should be the same as for HIV negative subjects. Antiretroviral agents have significant drug-drug interactions with many other medicines. These must always be taken into account when planning the treatment of HIV-infected patients.
Asunto(s)
Infecciones por VIH/complicaciones , Neoplasias/etiología , Antineoplásicos/efectos adversos , Terapia Antirretroviral Altamente Activa/efectos adversos , Interacciones Farmacológicas , Infecciones por VIH/tratamiento farmacológico , Humanos , Neoplasias/tratamiento farmacológico , Factores de RiesgoRESUMEN
Surgery with a margin of resection is the only curative form of treatment of soft tissue sarcoma. The combination of surgery and radiotherapy can, however, be used to lower the risk of local recurrence, if wide margins are not achieved e.g. in order to preserve the function of a limb. By using combination chemotherapy, disease recurrence can in the highest-risk patients be decreased to some extent. Radiotherapy provides palliative relief from a number of the patient's symptoms. The diagnosis and treatment of soft tissue sarcoma require an early participation of a multidisciplinary team familiarized with these rare tumors.
Asunto(s)
Extremidades , Grupo de Atención al Paciente , Sarcoma/radioterapia , Sarcoma/cirugía , Antineoplásicos/uso terapéutico , Terapia Combinada , Humanos , Recurrencia Local de Neoplasia/prevención & control , Cuidados Paliativos , Sarcoma/tratamiento farmacológicoRESUMEN
Cancer therapy agents can cause a vast spectrum of side effects which can be detected with various imaging techniques. These side effects can affect all organs and vary from non-symptomatic to fatal. The rapid evolution of cancer therapy brings constantly new agents into clinical practice. Some side effects may be detected only after the marketing approval of the therapy. The radiological findings usually lead into a suspicion of a drug side effect especially if there are no other imminent causes for the findings. Collaboration between the radiologist and the treating physician is essential in the diagnostic work-up.
Asunto(s)
Antineoplásicos/efectos adversos , Diagnóstico por Imagen , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Neoplasias/tratamiento farmacológico , HumanosRESUMEN
AIM: Our aims were to establish the 10-year overall and event-free survival rates among children and adolescents with bone sarcomas in Finland, estimate their respective incidences, evaluate the treatment given and describe the key prognostic factors. METHODS: We included 88 patients of <18 years of age diagnosed with a bone sarcoma during 1991-2005 in this retrospective, nationwide and population-based study. Median follow-up time was 12.2 years (range 5.8-20.3 years) for surviving patients. RESULTS: The overall incidence among children and adolescents was 5.1 per million: 3.6 for osteosarcoma, 1.2 for Ewing's sarcoma and 0.3 for chondrosarcoma. The 10-year event-free and overall survival of those with a localised disease at diagnosis was 69% and 82%, respectively. The overall 10-year survival of those with a metastatic disease at diagnosis was 47%. Prognostic factors for localised disease included an axial versus peripheral primary tumour site in Ewing's sarcoma (p = 0.022) and age at diagnosis in osteosarcoma (p = 0.027). CONCLUSION: The 10-year overall survival of children and adolescents diagnosed with a bone sarcoma in Finland during 1991 to 2005 was very good, at 82% if the disease was localised at diagnosis and 47% if it was metastatic at diagnosis.
Asunto(s)
Neoplasias Óseas/epidemiología , Neoplasias Óseas/terapia , Sarcoma/epidemiología , Sarcoma/terapia , Adolescente , Factores de Edad , Neoplasias Óseas/diagnóstico , Niño , Preescolar , Terapia Combinada , Femenino , Finlandia/epidemiología , Humanos , Incidencia , Lactante , Recién Nacido , Masculino , Pronóstico , Estudios Retrospectivos , Sarcoma/diagnóstico , Tasa de SupervivenciaRESUMEN
BACKGROUND: Most local recurrences have developed in the clinical target volume in previously published series after combined modality treatment for soft tissue sarcoma. However, marginal misses were seen in almost 20% of the patients. The aim of the present study was to determine the location of the recurrence and the total dose at the centre point of the local recurrence for future radiation therapy planning. MATERIAL AND METHODS: We included only patients with images in digital form, during 1999-2006 (n = 17), treated for soft tissue sarcoma with combined surgical therapy and radiotherapy at Helsinki University Central Hospital. Image fusion was used to determine the location of the recurrence in relation to radiation therapy target. RESULTS: In the present study utilising digital image fusion, in patients with 3D CT-based radiation treatment planning the risk of marginal miss was low as only one patient of 17 relapsed outside the target. Estimated mean radiation dose at the site of local recurrence was 49.1 Gy in patients with positive margins and 48.1 Gy in patients with negative margins. CONCLUSION: The risk of marginal miss in soft tissue sarcoma is low after modern 3D planned radiation treatment combined with surgery. More generous use of boost might improve in-target local control.